Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

3.296 +0.146 (+4.63%)
Streaming Delayed Price Updated: 1:43 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 201,495
Open 3.150
Bid (Size) 3.270 (8)
Ask (Size) 3.300 (8)
Prev. Close 3.150
Today's Range 3.100 - 3.390
52wk Range 2.655 - 20.40
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
From 23andMe, Inc.
Via GlobeNewswire
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives. 
Via Benzinga

Performance

YTD
-81.86%
-81.86%
1 Month
-32.60%
-32.60%
3 Month
-50.62%
-50.62%
6 Month
-68.51%
-68.51%
1 Year
-80.91%
-80.91%

More News

Read More
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For 23andMe Holding
Via Benzinga
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
From 23andMe, Inc.
Via GlobeNewswire
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
ASML's Latest Chapter in the Semiconductor Story
Via The Motley Fool
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
From 23andMe, Inc.
Via GlobeNewswire
Author Alok Sama on OpenAI, Bubbles, and When to Sell
Via The Motley Fool
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Mathew Knowles as New Brand Ambassador
From 23andMe, Inc.
Via GlobeNewswire
Legal Battle Brews Over 23andMe's Customer Data Breach Settlement And Arbitration Claimants
Via Benzinga
Topics Data Breach
Exposures Information Security
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
From 23andMe, Inc.
Via GlobeNewswire
Independent Board Members Of Penny Stock 23andMe Resign, Call Out CEO Anne Wojcicki For Not 'Actionable Proposal' Despite Ample Time
Via Benzinga
General Mills, Steelcase And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
From 23andMe, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.